SOMATOSTATIN AND PRIMARY HYPERPARATHYROIDISM

No satisfactory medical therapy exists for the treatment of primary hy perparathyroidism. Calcitonin and diphosphonates do not give good long -term control. This work examines the efficacy of the somatostatin ana logue octreotide in the management of hyperparathyroidism. Twenty-one patients were admitted before parathyroid surgery and were treated for 6 days with subcutaneous octreotide 100 mu g twice daily. Fasting blo od samples were taken for determination of serum levels of calcium and parathyroid hormone, and 24-h urinary calcium excretion was measured before and after treatment. A significant decrease in urinary calcium was demonstrated, but the reduction in serum calcium level was not sta tistically significant and there was no change in serum parathyroid ho rmone concentration. Octreotide may provide therapy for patients with hyperparathyroidism and for those who have undergone unsuccessful neck exploration or who are unfit for operation. It may ameliorate hyperca lciuria and reduce stone formation. The octapeptide may also have a po tential role as a diagnostic test in primary hyperparathyroidism by de termining the symptomatic effect of reducing raised levels of serum an d urinary calcium.